DENVER – The definition of distinct subgroups has not been as successful in small cell lung cancer (SCLC) as it has been in non-small cell lung cancer (NSCLC). Investigators have now described the clinical, pathologic, and molecular characteristics in a subgroup of SCLCs in never-smoking patients.
DENVER – Refined models have been developed to better predict outcomes for patients with malignant pleural mesothelioma who are candidates for cytoreductive surgery. These prognostic models may provide a more accurate and minimally invasive method for predicting outcomes for patients who are surgical candidates, as well as determine patients who may benefit from chemotherapy.
DENVER – Investigators have identified the molecular mechanisms underlying RET rearrangement, a genetic alteration recognized as a driver mutation in a small subset of lung adenocarcinoma.
DENVER – A new study shows that immunohistochemical (IHC) analysis is sensitive, specific, and accurate for detecting ALK protein expression based on gene rearrangement in non-small cell lung cancer (NSCLC).
ELCC 2014: Lung adenocarcinoma with RET fusion: early experience with diagnosis and targeted therapy
Drs. Oliver Gautschi and Lukas Bubendorf discourse on the presence of RET aberrations in NSCLC.
Dr. Tony Mok, President of IASLC, offers an overview on most common toxicities related to targeted therapies in NSCLC.